DiaMedica Therapeutics Inc. (DMAC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 29.28M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 4.15M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -39.23M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $29.28M | (m) | $4.15M | $-39.23M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $26.95M | (m) | $3.80M | $-36.73M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $24.61M | (m) | $3.85M | $-34.40M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $24.39M | (m) | $3.24M | $-33.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $22.93M | (m) | $2.79M | $-31.45M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $21.04M | (m) | $2.46M | $-29.08M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $19.06M | (m) | $2.08M | $-26.68M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $16.26M | (m) | $1.95M | $-24.11M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $14.55M | (m) | $1.81M | $-22.38M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $13.17M | (m) | $1.75M | $-21.49M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $13.11M | (m) | $1.68M | $-21.27M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $11.70M | (m) | $1.64M | $-19.39M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $10.07M | (m) | $1.63M | $-17.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $9.48M | (m) | $1.62M | $-15.99M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $7.84M | (m) | $1.50M | $-14.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $7.44M | (m) | $1.39M | $-13.27M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $8.13M | (m) | $1.27M | $-13.56M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $8.33M | (m) | $1.35M | $-13.56M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $8.77M | (m) | $1.56M | $-13.65M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $10.10M | (m) | $1.77M | $-14.67M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $9.92M | (m) | $1.97M | $-14.57M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $9.37M | (m) | $1.96M | $-13.91M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $8.31M | (m) | $1.84M | $-12.70M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $6.99M | (m) | $1.74M | $-11.20M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $6.43M | (m) | $1.68M | $-10.54M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $6.67M | (m) | $1.43M | $-10.58M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $7.90M | (m) | $1.16M | $-11.59M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $7.55M | (m) | $828.00K | $-10.94M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $7.14M | (m) | $487.00K | $-9.77M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $6.34M | (m) | $597.00K | $-8.88M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.52M | (m) | $620.00K | $-6.76M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $3.21M | (m) | $409.00K | $-4.52M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |